Deflazacort Oral Suspension

Deflazacort Oral Suspension belongs to the Suspensions category within the Anti-Inflammatory and Immunomodulators therapeutic segments. It is an oxazoline derivative of prednisolone with potent anti-inflammatory activity.

For pharmaceutical marketing companies, this is a specialist corticosteroid product with consistent demand in rheumatology and immunology. Saar Biotech manufactures it from our manufacturing facility in Baddi.

At Saar Biotech, we manufacture Deflazacort Suspension using a controlled oral suspension manufacturing process that ensures dose uniformity, palatability, and packaging reliability.

• Suspension Uniformity: Deflazacort is uniformly distributed for consistent dosing.
• Taste Masking: Palatable suspension base ensures patient acceptance.
• pH and Stability Management: The active remains chemically stable for 24 months.
• 30ml and 60ml Pack Coverage: Suitable for both short and extended courses.

This suspension is manufactured and supplied by Saar Biotech for the following established clinical indications:

• Rheumatoid Arthritis: Management of inflammatory joint disease
• Asthma: Adjunctive therapy in severe asthma
• Allergic Conditions: Severe allergic disorders
• Duchenne Muscular Dystrophy: Corticosteroid therapy in DMD
• Inflammatory Skin Disorders: Severe dermatological conditions

Deflazacort is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammatory mediators. It reduces inflammation, immune response, and allergic reactions.

Manufacturing Integrity

• Suspension Uniformity: Deflazacort is uniformly suspended for consistent dosing.
• pH Stability: The suspension vehicle is pH-buffered to maintain active stability.

Saar Biotech provides Third-Party Manufacturing and Contract Manufacturing for Deflazacort Suspension from our dedicated oral suspension manufacturing facility in Baddi, Himachal Pradesh.

• Facility: Oral suspension manufacturing area with controlled processing, automated bottle filling, capping, labelling, and carton packing lines.
• Capacity: Scalable from brand-entry launches to large commercial batches.
• Quality Lab: In-house GLP-certified lab with HPLC assay, pH, viscosity, MLT, and fill volume checks.
• Turnaround: New orders — 30 to 45 working days. Repeat orders — 20 to 25 working days.
• Packaging: 30ml and 60ml PET or dark amber bottles; sticker label, drip-off carton, measuring cup, printed cap.
• MOQ: Starting at 5,000–10,000 units per SKU.

1. Warehouse Conditions: Store below 30°C in a cool, dry environment. Do not freeze.
2. Shake Well Before Every Dose: Critical for uniform API distribution.
3. Measuring Cup Use: A calibrated measuring cup ensures accurate dosing.
4. Light Protection: Dark amber bottles and outer cartons protect from light-induced degradation.

Every commercial batch is quarantined until it passes a comprehensive analytical release protocol:

• HPLC Assay: Quantification of Deflazacort 6mg per 5ml.
• Suspension Uniformity: Sediment behaviour and re-dispersibility testing.
• pH & Viscosity Testing: Suspension stability monitoring.
• Microbial Limit Testing (MLT): IP-compliant microbiological testing.
• Certificate of Analysis (COA): Issued with every B2B batch.

• Corticosteroid Side Effects: Weight gain, mood changes, insomnia, gastrointestinal effects.
• Prolonged Use: Osteoporosis, adrenal suppression, growth suppression in children.
• Contraindications: Systemic fungal infections; hypersensitivity.
• Precautions: Diabetes, hypertension, osteoporosis, glaucoma, gastrointestinal disorders.

For third-party manufacturing enquiries, private-label contracts, or to request pricing and packaging options for Deflazacort Oral Suspension, please use the B2B enquiry form below.